Shape the future of CNS drug development at Lundbeck
Haeger & Carlsson, on behalf of Lundbeck, are recruiting an In Vitro Drug Interaction Scientist.
As Principal Scientist – in vitro Drug-Drug Interaction (DDI), you will play a key role in the evaluation and prediction of DDI risks for Lundbeck’s development compounds, ensuring safe and effective therapies reach patients. Moreover, as a Departmental representative in the project teams, you will be part of defining the strategy for the projects and will be involved in interactions with health authorities.
To support the projects, you will be designing, conducting, interpreting in vitro DDI studies, and develop PBPK models for DDI risk assessment. You will present the outcome to the project teams and guide decision-making in both preclinical and clinical development. Furthermore, for the development projects that you are responsible for, you will be developing the PBPK strategy throughout the development together with the cross functional PBPK team.
Qualification Requirements
Preferred Qualifications and Attributes
We are seeking a robust, resilient, and senior scientist who thrives on scientific challenges and collaborative teamwork. You are proactive, quality-focused, and committed to delivering results that make a real difference for patients.
Lundbeck is a global pharmaceutical company dedicated to restoring brain health so every person can be their best. For more than 70 years, they have been at the forefront of discovering, developing, and delivering innovative medicines for people living with psychiatric and neurological disorders. Lundbeck pride themselves on scientific excellence, collaboration, and a deep commitment to improving lives.
On site: At least 4 days/week
Please read more at https://www.lundbeck.com/global
Please apply through haegercarlsson.com.
Questions are answered by:
Alexander Johansson, +46 (0)73 – 77 77 233, alexander@haegercarlsson.com
Rolf Carlsson, +46 (0)70-316 12 68, rolf@haegercarlsson.com